2BPIS-C300Circadia C300 Contactless Cardiorespiratory Monitor

The Circadia C300 System TM Instructions for Use Circadia C300 System TM - Instructions for Use - September 26, 2025 revision #4 1 Table of Contents Table of Contents 2 Introduction 3 Quick start 5 Indications for use 6 Safety Information, Warnings and Cautions 6 Safety Warnings and Cautions 6 Performance Warnings and Cautions 7 Cleaning, Disinfecting, and Service Warnings and Cautions 7 Compliance Warnings and Cautions 8 Cybersecurity Warnings and Cautions: 8 Contraindications: 8 About the Circadia C300 System technology 9 Overview 9 Contents of the C300 System packaging 10 Overview of Display Parameters in the CIP App 10 Operation 11 Initial installation and configuration of the Circadia Monitor 11 Initial download and use of the CIP App 12 Navigating the CIP App 12 Clinical Tab 13 Patient Profile 13 Watchlist Tab 15 Consents & Devices Tab 15 Motion & Exits Tab 15 Settings 17 Patient Monitoring and Data Review 18 Start monitoring 18 Review Respiratory and Heart Rate data 18 Performing a Respiratory Rate and Heart Rate spot measurement 18 Motion and Exit Data Review and Notifications 18 Stop monitoring 19 Troubleshooting 19 Expected service life 20 System maintenance 20 Cleaning 20 Disposal 21 Mobile Device Requirements 21 Wi-Fi network requirements 21 Specifications 22 Circadia C300 System TM - Instructions for Use - September 26, 2025 revision #4 2 EMC emissions 24 EMC immunity 25 RF immunity 26 Recommended separation distance 27 Wireless Coexistence immunity 28 Symbols and certifications 29 Warranty 30 Circadia C300 System TM - Instructions for Use - September 26, 2025 revision #4 3 Introduction This manual provides the necessary instructions to operate and receive valid measurements from the Circadia C300 System. In addition, it contains the regulatory and safety information as well as technical specifications of the system. Do not operate the Circadia C300 System without completely reading and understanding these instructions. The Circadia C300 System (the “System”) consists of the Circadia Contactless Cardiorespiratory Monitor, Model: C300 (the “Monitor”), the Circadia Clinical Intelligence Platform application (the “CIP App”), and the Circadia Cloud Service (the “Cloud Service”). The purpose of the Circadia C300 System is to measure respiratory rate (RR) and heart rate (HR) from a patient while seated or lying in bed, under no-motion conditions, including spot measurements. The System is intended as an adjunct to standard care and not intended to replace other physical vital signs parameters and patient information, for retrospective data analysis, to detect changes in vital signs over time. The system is intended to be used by healthcare professionals and data are intended to be reviewed by healthcare professionals to inform patient care. The System is not intended for active monitoring of RR and HR, as it does not provide alarms for timely response in life-threatening situations. The System may be used for long-term unsupervised use, and it may be used to obtain on-demand spot-check measurements. It is designed to automatically discard values for HR and RR that may be inaccurate or artefactual. The system is not indicated to monitor heart rate in patients with arrhythmias, such as atrial fibrillation. The System is also intended to monitor motion, user presence or absence in the vicinity of the Monitor, and exits from the vicinity of the Monitor. Presence and exit data are available in real time, but should not be used as a sole basis for medical decisions or patient care management, and should not replace standard care practices. The CIP App is a cloud-based web application that operates on both mobile and desktop devices, and allows a user to visualize long-term data from multiple connected Monitors. For optimal monitoring performance, the Monitor must be placed to the side of the patient, at a distance of 3 ft or less from the patient’s chest, with no other motion in the direct vicinity. The successful operation of the System assumes basic knowledge of using iOS mobile devices (tablets and smartphones). Circadia C300 System TM - Instructions for Use - September 26, 2025 revision #4 4 Quick start 1. Download and Install App 1.1. Using an iOS mobile device, go to your device’s app store. 1.2. Search for “Circadia CIP” (Developer: Circadia Technologies, Ltd.) and download it. 2. Launch the App 2.1. Tap the Circadia CIP icon on your home screen. 3. Login to the App 3.1. Enter your login credentials provided by Circadia Health. 3.2. Note: If you do not have your credentials, contact Circadia Health Customer Support ([email protected]). 4. Enter One-Time Password (OTP) 4.1. A One-Time Password (OTP) will be sent to your registered mobile phone number. 4.2. Enter the OTP in the app. 5. Set up your 4-digit PIN 5.1. Choose and enter a 4-digit PIN for future quick sign-ins. 5.2. Note: Your PIN will be used for easy and secure access in the future. 6. Complete App Setup 6.1. The CIP App setup is now complete. 6.2. You will be directed to the dashboard. 7. Circadia Monitor Setup 7.1. Circadia Monitors will be installed and configured by the Circadia Health Team. If your CIP App does not display the Monitors, contact Circadia Health Customer Support. 7.2. Ensure the Monitor stays connected to power using the provided power cable. 7.3. Ensure the Monitor is at a distance up to 3 ft to the patient, pointed at their chest. 8. Start Monitoring 8.1. Data will stream automatically from the Monitor, and will be visible in the CIP App . 8.2. It may take several hours before data is being displayed: The Monitor only collects RR and HR while the patient is at rest in bed. 8.3. For best performance, ensure the Monitor has direct line of sight to the patient, and no other motion is present in the Monitor’s detection range (5 ft). 8.4. To measure RR and HR on-demand, ensure correct Monitor placement, and ask the patient to lie still. RR and HR will be displayed (updating minutely) in the CIP Ap…

Text truncated - open the document above for the full version.

Grantee also Agent for Service of Process_FCC_Attestation Statements_Kiwa Page 1 of 2 RF_754_02 15-02-2023 U.S. Agent Designation for Service of Process (Applicant is Both Grantee and U.S. Agent) TO: Kiwa Nederland B.V. Wilmersdorf 50 7327 AC Apeldoorn Postbus 137 7300 AC Apeldoorn Netherlands ATTENTION: FCC Certification – Section 2.911(d)(7) Information This letter is to confirm that the Applicant will also serve as the U.S. Agent for Service of Process as required by 47 CFR 2.911(d)(7). The Applicant acknowledges that they must maintain an agent for no less than one year after terminating all marketing and importation OR the conclusion of any Commission-related proceeding involving the equipment. The Applicant further acknowledges their responsibility to inform the FCC whenever the Designated U.S. Agent information changes. Applicant & Agent Company name: Circadia Health, Inc. FRN: 0036642031 Grantee Code: 2BPIS Contact person name: Erhan Ilhan Agent name: Erhan Ilhan Street address: 507 S Douglas St. ZIP/City/State 90245/El Segundo/CA Telephone number: +1 (805) 304-2072 Email address: [email protected] Signature Contact person*: Date: September 16, 2025 Signature Agent*: Date: September 16, 2025 Grantee also Agent for Service of Process_FCC_Attestation Statements_Kiwa Page 2 of 2 RF_754_02 15-02-2023 Note *Must be signed by both the applicant, and agent on behalf Audit trail Details FILE NAME RF_754_02, Agent Letter_B_Grantee also Agent_for Service of Process_FCC.docx - 9/16/25, 4:53 PM STATUS Signed STATUS TIMESTAMP 2025/09/16 23:54:39 UTC Activity SENT [email protected] sent a signature request to: Erhan Ilhan ([email protected]) 2025/09/16 23:54:05 UTC SIGNED Signed by Erhan Ilhan ([email protected]) 2025/09/16 23:54:39 UTC COMPLETED This document has been signed by all signers and is complete 2025/09/16 23:54:39 UTC The email address indicated above for each signer may be associated with a Google account, and may either be the primary email address or secondary email address associated with that account.

Covered list attestation FCC application letter Kiwa Page 1 of 2 RF_755_02 15-02-2023 Certification Application Attestation Statements Circadia Health, Inc. 507 S Douglas St 90245 El Segundo, CA. USA. Subject: FCC ID: 2BPIS-C300 To Whom It May Concern: Statement for 47 CFR section 2.911(d)(5)(i) Circadia Health, Inc certifies that as of the date of the application the equipment for which authorization is sought is not “covered” equipment 1 prohibited from receiving an equipment authorization pursuant to section 2.903 of the FCC rules. If the equipment for which the applicant seeks authorization is produced by any of the entities identified on the current Covered List, including affiliates or subsidiaries of the named companies, the applicant must include an explanation on why the equipment is not “covered” equipment. Additional Explanation: <N/A> Statement for 47 CFR section 2.911(d)(5)(ii) Circadia Health, Inc. (“the applicant”) certifies that, as of the date of the filing of this application, the applicant ☐ - is / X- is not (3) identified on the Covered List as an entity producing “covered” equipment. Date: September 26, 2025 City: El Segundo Name (2) : Erhan Ilhan Function: Head of Quality and Regulatory FRN: 0036642031 Telephone number: +1 (805) 304-2072 Email address: [email protected] Signature: 1 - The Commission’s Covered List is published by the Public Safety and Homeland Security Bureau and posted on the Commission’s website. This Covered List, which is periodically updated, identifies particular equipment, produced by particular entities, that constitutes “covered” equipment. https://www.fcc.gov/supplychain/coveredlist . (2): For FCC it must be the Grantee Code “owner” or the authorized agent. (3): double click on the appropriate box and select ‘’checked” then “OK” Audit trail Details FILE NAME RF_755_02, Covered_List_Attestation_FCC_Application Letter_Kiwa.docx - 9/26/25, 3:34 PM STATUS Signed STATUS TIMESTAMP 2025/09/26 22:35:44 UTC Activity SENT [email protected] sent a signature request to: Erhan Ilhan ([email protected]) 2025/09/26 22:34:59 UTC SIGNED Signed by Erhan Ilhan ([email protected]) 2025/09/26 22:35:44 UTC COMPLETED This document has been signed by all signers and is complete 2025/09/26 22:35:44 UTC The email address indicated above for each signer may be associated with a Google account, and may either be the primary email address or secondary email address associated with that account.

RF_160_05 Declaration of Authorisation Date of issue 02-01-2023 Declaration of Authorization We Name: Circadia Health, Inc. Address: 507 S Douglas St. City: El Segundo, CA 90245 Country: USA Declare that: Name Representative of agent: Daniel Sims (1) Agent Company name: Kiwa Ltd Address: Arnolds Court, Arnolds Farm Lane City: Mountnessing, Brentwood Country UK is authorized to apply for Certification of the following product(s): Product description: The Circadia C300 Contactless Cardiorespiratory Monitor Type designation: C300 Trademark: Circadia Health, Inc. Validity/expiry date: Valid until revoked on our behalf. Date: September 16, 2025 City: El Segundo, CA 90245 Name: Erhan Ilhan (2) Function: Head of Quality and Regulatory Signature: Notes: (1): Required for FCC application (2): For FCC it must be the Grantee Code “owner” or the authorized agent. Audit trail Details FILE NAME RF_160_05, Declaration of authorization.docx - 9/16/25, 4:06 PM STATUS Signed STATUS TIMESTAMP 2025/09/16 23:07:03 UTC Activity SENT [email protected] sent a signature request to: Erhan Ilhan ([email protected]) 2025/09/16 23:06:25 UTC SIGNED Signed by Erhan Ilhan ([email protected]) 2025/09/16 23:07:03 UTC COMPLETED This document has been signed by all signers and is complete 2025/09/16 23:07:03 UTC The email address indicated above for each signer may be associated with a Google account, and may either be the primary email address or secondary email address associated with that account.

FCC, Request for non-disclosure Date: 23- 06-2023 RF_501, Issue 11 Page 1 of 2 Company Name: Circadia Health, Inc. Address: 507 S Douglas St City: El Segundo, CA 90245 Country: USA To: Kiwa Netherlands B.V., Dept. FCC TCB Wilmersdorf 50 7327 AC Apeldoorn The Netherlands Subject: Request for confidentiality FCC ID: 2BPIS-C300 Reference number: Dear FCC TCB, 1. Long-Term Confidentiality Pursuant to 47 CFR Section 0.459(a) & (b), we hereby requests non-disclosure and confidential treatment of the following materials submitted in support of FCC certification application: ☐ Bill(s) of Material X Block Diagrams X Operational Description X Schematic Diagrams ☐ Tune-up Procedure Above materials contain secrets, proprietary and technical information, which would customarily be guarded from competitors under 47 CFR, section 0.457(d)(2). Disclosure or publication or any portion of this company confidential material to other parties could cause substantial competitive harm and provide unjustified benefits for competitors. 2. Short-Term Confidentiality (STC) -N/A Pursuant to Public Notice DA 04-1705 of the Commission’s policy, in order to comply with the marketing regulations in 47 CFR §2.803 and the importation rules in 47 CFR §2.1204, applicant hereby requests Short-Term Confidential treatment of the following materials (See notes below): ☐ Internal Photos ☐ User’s Manual ☐ Test Set-up Photos ☐ External Photos Justification: N/A Date: September 26, 2025Name and signature of applicant: Daniel Sims (Agent) Notes: 1) A document or type of document can only have ONE type of confidentiality! 2) Short-Term confidentiality is in principle for 45 days from date of grant; it can be extended max 3 times (total time 180 days max.)! The planned date should state in the RF731 application form. 3) FCC must be informed when marketing begins earlier. 4) Release takes place automatically thus extension must be requested in time. Telefication does not remind you of this! 5) Request for extension or for release must be received by Kiwa NL B.V. at least 7 days before date of actual marketing or before expiration of the STC period

Declaration of non-usage of external phase-locking inputs Date: September 16, 2025 Attention director of certification To Whom It May Concern: As per the requirement under 47 CFR 15.255(h), and RSS-210 Annex J.7 we hereby declare that the Circadia C300 Contactless Cardiorespiratory Monitor product is not equipped with any external phase-locking inputs that permit beam-forming arrays to be realized. By: Erhan Ilhan (Signature 1 ) (Print name) Title: Head of Quality and Regulatory On behalf of: Circadia Health, Inc. Telephone: +1 (800) 985-5596 1 Must be signed by FCC / ISED registered person on file for the company 1 Circadia Health, Inc. Audit trail Details FILE NAME KEC_FCC_002 Declaration of non usage of external phase locking inputs.docx - 9/16/25, 4:14 PM STATUS Signed STATUS TIMESTAMP 2025/09/16 23:14:41 UTC Activity SENT [email protected] sent a signature request to: Erhan Ilhan ([email protected]) 2025/09/16 23:14:05 UTC SIGNED Signed by Erhan Ilhan ([email protected]) 2025/09/16 23:14:41 UTC COMPLETED This document has been signed by all signers and is complete 2025/09/16 23:14:41 UTC The email address indicated above for each signer may be associated with a Google account, and may either be the primary email address or secondary email address associated with that account.

External Photos J14955 Front view Rear view Left side view Right side view Underside view

Proposed Labeling Proposed Labeling This proposed labeling section includes representative copies of the draft product label, draft Instructions for Use, and draft box labeling. Draft Product Label Draft product label shown below, to be placed on the back of the C300 Monitor. Red box indicates placement of on-device label (further specified below). Smallest label font size: 4pt. Product labeling. Graphics color: Pantone Cool Gray 11c, matte finish. Red square indicates placement of on-device label. The Circadia C300 System Page 1 Proposed Labeling Draft On-Device Labeling On-device label to be positioned on the back of the C300 Monitor, just underneath the USB-C connection port as outlined in the draft product label (above; red rectangle). It will be printed in black on white on a laminated material. The format of the label is as outlined below: The label will contain: ● GS1 datamatrix, contain all relevant fields (SN#, GTIN, DoM, LOT#) ● SN: 12-character serial number ● GTIN: 14-character GS1 GTIN for C300 ● Date of manufacture (MM/DD/YYYY) ● LOT: 4-character LOT number Power Adapter Labeling Power adapter uses the original manufacturer labeling with additional Circadia accessory GTIN and LOT #. Original manufacturer label on adapter Additional Circadia label on adapter The Circadia C300 System Page 2 Proposed Labeling Draft Box Labeling Master cartons The default packaging will be master cartons, in three types of quantities: 10x, 20x and 40x C300 Monitors. Each carton will have the following external labeling (dimensions in the example below are for the 40 pcs carton): ● 2 long sides will contain Circadia logo + text ● 1st short side will contain Circadia logo only ● 2nd short side will contain regulatory markings, manufacturer information and contents Draft box labeling, for the 40-pcs carton containing 40 C300 Monitors. Box dimensions and label layout are shown (top), and detailed design of box panels (bottom). The Circadia C300 System Page 3 Proposed Labeling Master Cartons Label - Detailed View Detailed view of box labeling - 2nd short side of master carton: The Circadia C300 System Page 4 Proposed Labeling The master carton label contains the following (from top to bottom): - Regulatory symbols - Manufacturer details - GTIN barcode for given size of master carton (different between sizes) - LOT# - Product reference - Quantity of what’s inside the box Ziploc Bags Individual C300 Monitors will be packed in bubble-padded Ziploc bags. Ziploc bags will have individual draft labeling as below: Front view Back view The Circadia C300 System Page 5 Proposed Labeling Detailed Ziploc bag labeling: The position indicated by a red box above in the above label draft will contain a label as below, with fields for: ● GTIN (01) ● Date of manufacture (11) ● Serial number (21) ● LOT number (10) The Circadia C300 System Page 6

Internal Photos J14955 Top side PCB: Top side PCB, 60GHz on chip radar antenna (highlighted) close up: Underside PCB:

1 (9) Copyright © Verkotan 2025 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Monitor_ID7668_17092025.docx RF Exposure Evaluation Report Date of Report: 17/09/2025 Client’s Contact person: Michal Maslik Number of pages: 9 Responsible Test engineer: Kalle Orava Testing laboratory: Verkotan Oy Elektroniikkatie 17 90590 Oulu Finland Client: Circadia Technologies Ltd 92 Albert Embankment Tintagel House London SE1 7TY UK Tested device: Circadia C300 Contactless Cardiorespiratory Monitor Related reports: - Testing has been carried out in accordance with: 47CFR §2.1091 Radiofrequency Radiation Exposure Evaluation: Mobile Devices 447498 D04 Interim General RF Exposure Guidance v01 Documentation: The test report must always be reproduced in full; reproduction of an excerpt only is subject to written approval of the testing laboratory Test Results: The EUT complies with the requirements in respect of all parameters subject to the test. The test results relate only to devices specified in this document Date and signatures: 17.09.2025 Laboratory Manager 2 (9) Copyright © Verkotan 2025 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Monitor_ID7668_17092025.docx TABLE OF CONTENTS 1. EVALUATION SUMMARY........................................................................................................................ 3 1.1 TEST DETAILS ......................................................................................................................................................................................... 3 1.2 EVALUATION RESULTS ..................................................................................................................................................................... 4 1.2.1 Standalone Exposure ................................................................................................................................................................... 4 1.2.2 Simultaneous Transmission Exposure................................................................................................................................. 4 2. DESCRIPTION OF THE DEVICE UNDER TEST (DUT)............................................................................... 5 2.1 SUPPORTED FREQUENCY BANDS AND OPERATIONAL MODES .............................................................................. 6 3. TEST EXCLUSIONS ................................................................................................................................... 7 4. RESULTS ................................................................................................................................................... 8 4.1 STANDALONE EXPOSURE ............................................................................................................................................................... 8 4.2 SIMULTANEOUS TRANSMISSION ANALYSIS ....................................................................................................................... 9 3 (9) Copyright © Verkotan 2025 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Monitor_ID7668_17092025.docx 1. EVALUATION SUMMARY 1.1 Test Details Device under Test (DUT): Product: Circadia C300 Contactless Cardiorespiratory Monitor Manufacturer: Circadia Technologies Ltd Model: C300 Hardware Version: C300 FCC ID: 2BPIS-C300 Mobile/Portable device: Mobile FCC Test Firm Designation Number: FI0005 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Monitor_ID7668_17092025.docx Document History: Initial version 4 (9) Copyright © Verkotan 2025 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Monitor_ID7668_17092025.docx 1.2 Evaluation Results 1.2.1 Standalone Exposure The device conforms to the requirements of the standards when the maximum ERP is less than or equal to the Test Exclusion Threshold Limit. Mode of Operation Maximum ERP [mW] Separation Distance [mm] MPE-Based Exemption threshold [mW] Evaluation Result 2.4 GHz WLAN 144.88 200 768 PASS 60GHz FMCW Radar 18.75 200 768 PASS 1.2.2 Simultaneous Transmission Exposure Highest Simultaneous Transmission SAR ∑ERP j / ERP th,j Limit Evaluation Result 2.4 GHz WLAN + 60GHz FMCW Radar 0.21 1 PASS 5 (9) Copyright © Verkotan 2025 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Monitor_ID7668_17092025.docx 2. DESCRIPTION OF THE DEVICE UNDER TEST (DUT) The C300 Monitor is a contactless cardiorespiratory monitor that is either wall-mounted above a patient’s bed or placed at a bedside table. The Monitor records heart rate and respiratory rate of adult patients in clinical settings such as hospitals and post-acute and long-term care facilities (e.g., nursing homes, skilled nursing facilities, inpatient rehabilitation facilities, long- term care hospitals). In addition, the Circadia C300 System is intended to monitor motion and user presence or absence in the vicinity of the Monitor. The Monitor continuously streams data to the Cloud Service over a 2.4GHz Wi-Fi network. Bio motion signals are monitored using a 60GHz FMCW radar unit. Figure 1. Overview of the DUT Exposure Environment General population, uncontrolled 6 (9) Copyright © Verkotan 2025 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Monitor_ID7668_17092025.docx 2.1 Supported Frequency Bands and Operational Modes TX Frequency bands Modes of Operation Transmitter Frequency Range [MHz] EIRP [dBm] 2.4 GHz WLAN 2412 – 2462 23.76 60GHz FMCW Radar 58000 – 61500 14.88 Origin of the EIRP information for Wlan is Sporton International RF Exposure Evaluation Report No. : FA1N0920 Kiwa 60 GHz FMCW Radar report number reference: 05-14955-4-25 Issue 01, shows EIRP measurement for the radar. 7 (9) Copyright © Verkotan 2025 Document ID: FCC_RF Exposure Evaluation_Circadia C300 Contactless Cardiorespiratory Moni…

Text truncated - open the document above for the full version.

Page 1 of 113 File Name: Circadia Technologies Ltd.14955-4 Issue 01 QMF21J - Issue 05 - KEC Issue 02; 47 CFR Part 15C Radio Test Report Circadia Technologies Ltd Circadia C300 Contactless Cardiorespiratory Monitor C300 47 CFR Part 15.255 Effective Date 1st October 2024 FDS: Part 15 Field Disturbance Sensor Test Date: 13th May 2025 to 22nd May 2025 Report Number: 05-14955-4-25 Issue 01 The testing was carried out by Kiwa Ltd trading as Kiwa Electrical Compliance, an independent test house, at their test facility located at: Kiwa Electrical Compliance Arnolds Court Arnolds Farm Lane Mountnessing Essex CM13 1UT U.K. www.Kiwa.com Telephone: +44 (0) 1277 352219 Email: [email protected] This laboratory is accredited in accordance with the recognised Internaonal Standard ISO/IEC 17025. This accreditaon demonstrates technical competence for a defined scope and the operaon of a laboratory quality management system (refer joint ISO-ILAC-IAF communiqué dated April 2017). This report is not to be reproduced by any means except in full and in any case not without the written approval of Kiwa Electrical Compliance. ©2025 Kiwa Electrical Compliance REPORT NUMBER: 05-14955-4-25 Issue 01 ALL RIGHTS RESERVED Page 2 of 113 File Name: Circadia Technologies Ltd.14955-4 Issue 01 QMF21J - Issue 05 - KEC Issue 02; 47 CFR Part 15C Arnolds Court, Arnolds Farm Lane, Mountnessing, Brentwood Essex, CM13 1UT Certificate of Test 14955-4 The equipment noted below has been fully tested by Kiwa Electrical Compliance and, where appropriate, conforms to the relevant subpart of 47 CFR Part 15C. This is a certificate of test only and should not be confused with an equipment authorisation. Other standards may also apply. Equipment: Circadia C300 Contactless Cardiorespiratory Monitor Model Number: C300 Unique Serial Number: c82b-9689-e79c Applicant: Circadia Technologies Ltd 92 Albert Embankment Tintagel House, London SE1 7TY UK Proposed FCC ID: 2BPIS-C300 Full measurement results are detailed in Report Number: 05-14955-4-25 Issue 01 Test Standards: 47 CFR Part 15.255 Effective Date 1st October 2024 FDS: Part 15 Field Disturbance Sensor DEVIATIONS: No deviations have been applied. Note: This report pertains to the 60 GHz radar functionality of the EUT only. Contains FCC ID 2AC7Z-ESPS3WROOM1. This certificate relates only to the unit tested as identified by a unique serial number and in the condition at the time it was tested. It does not relate to any other similar equipment and performance of the product before or after the test cannot be guaranteed. Whilst every effort is made to assure quality of testing, type tests are not exhaustive and although no non-conformances may be found, this doesn't exclude the possibility of unit not meeting the intentions of the standard or the requirements of the Federal Regulations, particularly under different conditions to those during testing. Any compliance statements are made reliant on (a) the application of the product and use of the assigned band being acceptable to the FCC and (b) the modes of operation as instructed to us by the Customer based on their specific knowledge of the application and functionality of the EUT. Statements of compliance, where measurements were made, do not include the measurement uncertainty. The measurement uncertainty, where stated, is the expanded uncertainty based on a standard uncertainty multiplied by a coverage factor of k=2, providing a level of confidence of approximately 95%. Date of Test: 13th May 2025 to 22nd May 2025 Test Engineer: Graham Blake Approved By: Test Development Engineer Customer Representative: ©2025 Kiwa Electrical Compliance REPORT NUMBER: 05-14955-4-25 Issue 01 ALL RIGHTS RESERVED Page 3 of 113 File Name: Circadia Technologies Ltd.14955-4 Issue 01 QMF21J - Issue 05 - KEC Issue 02; 47 CFR Part 15C 1 Contents 1 Contents .............................................................................................................................................................................. 3 2 Equipment under test (EUT) ................................................................................................................................................ 4 2.1 Equipment specification ............................................................................................................................................... 4 2.2 Applicant declarations for testing ................................................................................................................................. 5 2.3 Functional description .................................................................................................................................................. 5 2.4 Modes of operation ...................................................................................................................................................... 5 2.5 Emissions configuration ............................................................................................................................................... 6 3 Summary of test results ....................................................................................................................................................... 7 4 Specifications .......................................................................................................................................................................…

Text truncated - open the document above for the full version.